Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in PAD Patients.

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This study will evaluate the efficacy and safety of apixaban 2.5 mg twice daily plus aspirin compared to the standard treatment (clopidogrel plus aspirin) in patients with critical limb ischemia undergoing infrapopliteal arterial endovascular intervention.
Epistemonikos ID: 01c12bc26f0d32322de2c64ccddcc82a343534e2
First added on: May 07, 2024